Screener
ImmunityBio, Inc. IBRX Europe — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s europe — revenue?
- ImmunityBio, Inc. (IBRX) reported europe — revenue of $24K in Q1 2026.
- What is the long-term trend for ImmunityBio, Inc.'s europe — revenue?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s europe — revenue has grown at a -16.1% compound annual growth rate (CAGR), from $561K to $278K.
- What does europe — revenue mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products, licensing agreements, or clinical services within the European geographic market. It reflects the company's ability to successfully commercialize its immuno-oncology and cellular therapy pipeline in this specific regulatory and economic region. Fluctuations in this metric indicate the effectiveness of regional market penetration, local regulatory approvals, and the adoption rate of the company's therapeutic platforms by European healthcare providers.
Ask your AI about ImmunityBio, Inc.'s europe — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude